Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
James P Howard, Frances A Wood, Judith A Finegold, Alexandra N Nowbar, David M Thompson, Ahran D Arnold, Christopher A Rajkumar, Susan Connolly, Jaimini Cegla, Chris Stride, Peter Sever, Christine Norton, Simon A M Thom, Matthew J Shun-Shin, Darrel P Francis - Journal of the American College of Cardiology, 2021
Among patients who had stopped statins because of side effects, most statin-attributed symptoms were nocebo. Mean daily symptom intensity did not differ significantly between statin (16.3) and placebo (15.4) months (P=0.39), but both were markedly higher than no-tablet months (8.0, P<0.001), indicating symptoms were driven by the act of taking a tablet rather than the statin itself. The nocebo ratio was 0.90, meaning about 90% of the symptom burden on a statin was also experienced on placebo. This record is the open-access detailed analysis of the SAMSON trial (first reported as a brief letter, Wood et al., NEJM 2020), used here because its figures are publicly verifiable.
Key findings
- Among 60 patients (49 completed) who had previously stopped statins for side effects, mean daily symptom intensity was 8.0 during no-tablet months, 15.4 during placebo months, and 16.3 during statin months.
- There was no significant difference between statin and placebo months (16.3 vs 15.4, P=0.39), but both were markedly higher than no-tablet months (P<0.001).
- The nocebo ratio was 0.90, meaning about 90% of the symptom burden experienced on a statin was also experienced on placebo.
- Symptoms tracked the act of taking a tablet rather than the statin pharmacology, supporting a largely nocebo explanation for statin-attributed side effects.
Effect measures
- Other: Nocebo ratio 0.90 (about 90% of statin-attributed symptom burden also occurred on placebo)
- Other: Statin 16.3 vs placebo 15.4 mean daily symptom intensity (0-100 scale); difference not significantstatin 95% CI 13.0-19.6; placebo 95% CI 12.1-18.7; P=0.39
- Other: No-tablet 8.0 vs tablet (placebo or statin); both tablet arms significantly higherno-tablet 95% CI 4.7-11.3; P<0.001
Why this evidence tier (Moderate)
- Risk of bias:
- Randomized, double-blind n-of-1 crossover with placebo and no-treatment arms and app-based daily symptom capture - a rigorous within-patient design.
- Precision:
- Small sample (60 enrolled, 49 completed); the central estimate is clear, but the modest size contributes to the moderate rather than high tier.
- Directness:
- Directly measures whether statin-attributed symptoms exceed placebo, in exactly the patient group that had stopped statins for side effects.
- Consistency:
- Concordant with StatinWISE (Herrett 2021) and the broader statin nocebo literature.
- Funding / COI:
- Funded by the British Heart Foundation (PG/15/7/31235), which had no role in design, data collection, analysis, interpretation, or writing; individual author support from the Wellcome Trust (Howard), the NIHR (Nowbar), and the MRC (Rajkumar). The open-access paper states all other authors reported no relationships relevant to its contents, and no author reported a statin or pharmaceutical-company relationship - a clean COI profile, verified verbatim against the PMC full text.
Moderate certainty that most symptoms patients attribute to statins are nocebo - elicited by taking a tablet rather than by the drug - in patients who had previously discontinued for side effects.
- Population:
- 60 patients (49 completed) who had previously discontinued statin therapy because of side effects that had occurred within 2 weeks of starting treatment. Each took 12 one-month bottles (4 atorvastatin 20 mg, 4 placebo, 4 empty) in random sequence, reporting daily symptom intensity via a smartphone app.
- Conflicts of interest:
- Disclosure (verbatim, open-access paper): "All other authors have reported that they have no relationships relevant to the contents of this paper to disclose." No author reported a relationship with a statin or pharmaceutical company. Funded by the British Heart Foundation, which had no role in the study; individual fellowships from the Wellcome Trust, the NIHR, and the MRC. No retraction or erratum was found.
- Funding:
- British Heart Foundation (PG/15/7/31235), with no role in the study; individual author fellowships from the Wellcome Trust, the NIHR, and the MRC.
Limitations
- Small sample (60 enrolled, 49 completed), limiting precision.
- Enrolled only patients who had already stopped statins for side effects, so results may not generalize to all statin users.
- The trial was first reported as a brief NEJM letter (2020) without a formal abstract; the detailed figures used here are taken from the open-access JACC analysis (2021) of the same trial.